Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/takara-holdings-inc" target="_blank" data-smartkarma-citation="entities:11074:1" rel="noopener">Takara Holdings (2531 JP)</a> has been under pressure from activist Value Act. Friday they announced they would buy out their major listed subsidiary <a href="https://www.smartkarma.com/entities/takara-bio-inc" target="_blank" data-smartkarma-citation="entities:10766:1" rel="noopener">Takara Bio Inc (4974 JP)</a>. </li>
<li>The premium is at 43+%. That's pretty good, but the Tender Offer at ¥1,150/share is below the price at which it traded for a decade til two years ago.</li>
<li>This will almost certainly get done. By itself, it doesn't seem to be an activist bumpitrage target. </li>
</ul>



Takara Holdings (2531 JP) has been under pressure from activist Value Act. Friday they announced they would buy out their major listed subsidiary Takara Bio Inc (4974 JP). 
The premium is at 43+%. That's pretty good, but the Tender Offer at ¥1,150/share is below the price at which it traded for a decade til two years ago.
This will almost certainly get done. By itself, it doesn't seem to be an activist bumpitrage target. 


[Japan M&A] Activist-Pressured Takara Holdings (2531) Takes Out Sub Takara Bio (4974)

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/takara-holdings-inc" target="_blank" data-smartkarma-citation="entities:11074:1" rel="noopener">Takara Holdings (2531 JP)</a> has launched tender offer for the ordinary shares of <a href="https://www.smartkarma.com/entities/takara-bio-inc" target="_blank" data-smartkarma-citation="entities:10766:1" rel="noopener">Takara Bio Inc (4974 JP)</a> at the price of ¥1,150 per share to acquire all the shares.</li>
<li>Currently, Takara Holdings holds 73,350,000 shares in Takara Bio, representing a controlling ownership of 60.91%. Takara Holdings plans to make Takara Bio its wholly owned subsidiary.</li>
<li>Amid bleak outlook for the operating environment, no near-term performance improvement is expected for Takara Bio. It will be wise to tender shares in the offer.</li>
</ul>



Takara Holdings (2531 JP) has launched tender offer for the ordinary shares of Takara Bio Inc (4974 JP) at the price of ¥1,150 per share to acquire all the shares.
Currently, Takara Holdings holds 73,350,000 shares in Takara Bio, representing a controlling ownership of 60.91%. Takara Holdings plans to make Takara Bio its wholly owned subsidiary.
Amid bleak outlook for the operating environment, no near-term performance improvement is expected for Takara Bio. It will be wise to tender shares in the offer.


Takara Bio (4974 JP): Timely Tender Offer from Takara Holdings (2531 JP) To Delight Shareholders

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/takara-bio-inc" target="_blank" data-smartkarma-citation="entities:10766:1" rel="noopener">Takara Bio Inc (4974 JP)</a> has recommended a tender offer from <a href="https://www.smartkarma.com/entities/takara-holdings-inc" target="_blank" data-smartkarma-citation="entities:11074:1" rel="noopener">Takara Holdings (2531 JP)</a> at JPY1,150, a 43.6% premium to the last close. </li>
<li>The offer is arguably attractive as it is above the midpoint of the IFA DCF valuation range and implies a P/B of 1.37x. </li>
<li>However, the offer is light compared to historical trading ranges and is opportunistically timed. Nevertheless, the low required tendering rate points to a done deal.</li>
</ul>



Takara Bio Inc (4974 JP) has recommended a tender offer from Takara Holdings (2531 JP) at JPY1,150, a 43.6% premium to the last close. 
The offer is arguably attractive as it is above the midpoint of the IFA DCF valuation range and implies a P/B of 1.37x. 
However, the offer is light compared to historical trading ranges and is opportunistically timed. Nevertheless, the low required tendering rate points to a done deal.


Takara Bio (4974 JP): Takara Holdings (2531 JP)’s Tender Offer Is Light but Done

David Blennerhassett

<ul>
<li>For April 2026, 8 new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$7bn.</li>
<li>The average premium for the new transactions announced (or first discussed) in April was ~56%, and a year-to-date average of 45%.</li>
<li>The average premiums for transactions in 2025, 2024, 2023, 2022, 2021, 2020, and 2019 were 49%, 43%, 39%, 41%, 33%, 31%, and 31%.</li>
</ul>


For April 2026, 8 new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$7bn.
The average premium for the new transactions announced (or first discussed) in April was ~56%, and a year-to-date average of 45%.
The average premiums for transactions in 2025, 2024, 2023, 2022, 2021, 2020, and 2019 were 49%, 43%, 39%, 41%, 33%, 31%, and 31%.


Asia-Pac M&A, April 2026 Wrap: Atlas Arteria, European Lithium, OOh!Media, Global Ltd, Taiyo Holding

<ul>
<li>I tally 23 - mostly firm, mostly Asia-Pac - arb transactions currently being discussed and analysed on Smartkarma. Those arbs metrics and upcoming events are detailed below.</li>
<li>One new deal was discussed on Smartkarma this week: <a href="https://www.smartkarma.com/entities/global-ltd-the" target="_blank" data-smartkarma-citation="entities:9672:1" rel="noopener">Global (3271 JP)</a>. Both <a href="https://www.smartkarma.com/entities/ronzgun-international-holdings" target="_blank" data-smartkarma-citation="entities:40082:1" rel="noopener">Rongzun (1780 HK)</a> and <a href="https://www.smartkarma.com/entities/beijingwest-industries-interna" target="_blank" data-smartkarma-citation="entities:13118:1" rel="noopener">BeijingWest Industries (2339 HK)</a> are suspended pursuant to the Hong Kong Takever's Code.</li>
<li>Key updates/news also took place on: <a href="https://www.smartkarma.com/entities/insignia-financial-ltd" target="_blank" data-smartkarma-citation="entities:12349:1" rel="noopener">Insignia Financial (IFL AU)</a>, <a href="https://www.smartkarma.com/entities/national-storage-reit" target="_blank" data-smartkarma-citation="entities:13762:1" rel="noopener">National Storage REIT (NSR AU)</a>, <a href="https://www.smartkarma.com/entities/bright-smart-securities-commodities-group" target="_blank" data-smartkarma-citation="entities:20511:1" rel="noopener">Bright Smart Securities (1428 HK)</a>, <a href="https://www.smartkarma.com/entities/mcj-co-ltd" target="_blank" data-smartkarma-citation="entities:14132:1" rel="noopener">MCJ (6670 JP)</a>, and <a href="https://www.smartkarma.com/entities/takara-bio-inc" target="_blank" data-smartkarma-citation="entities:10766:1" rel="noopener">Takara Bio Inc (4974 JP)</a>.</li>
</ul>


I tally 23 - mostly firm, mostly Asia-Pac - arb transactions currently being discussed and analysed on Smartkarma. Those arbs metrics and upcoming events are detailed below.
One new deal was discussed on Smartkarma this week: Global (3271 JP). Both Rongzun (1780 HK) and BeijingWest Industries (2339 HK) are suspended pursuant to the Hong Kong Takever's Code.
Key updates/news also took place on: Insignia Financial (IFL AU), National Storage REIT (NSR AU), Bright Smart Securities (1428 HK), MCJ (6670 JP), and Takara Bio Inc (4974 JP).


Asia-Pac M&A Weekly Wrap: The Global, Insignia Financial, National Storage REIT, MCJ, Takara Bio

Japan

TAKARA BIO INC. is a biopharmaceutical company.  The Company researches and develops reagents for genome engineering and analysis, technology used for gene therapy, and natural health food products using mushrooms and seaweed body and extracts.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Takara Bio Inc (4974 JP)

[Japan M&A] Activist-Pressured Takara Holdings (2531) Takes Out Sub Takara Bio (4974)

Takara Standard, under pressure from Value Act (who owns 15%) to Do Something, has announced a buyout of listed sub Takara Bio. This is a 43%...

Travis Lundy

Takara Bio (4974 JP): Timely Tender Offer from Takara Holdings (2531 JP) To Delight Shareholders

Takara Holdings has launched tender offer for the ordinary shares of Takara Bio at the price of ¥1,150 per share to acquire all the shares....

Tina Banerjee

Takara Bio (4974 JP): Takara Holdings (2531 JP)’s Tender Offer Is Light but Done

The offer is light compared to historical trading ranges and is opportunistically timed. Nevertheless, the low required tendering rate points to a...

Arun George

Asia-Pac M&A, April 2026 Wrap: Atlas Arteria, European Lithium, OOh!Media, Global Ltd, Taiyo Holding

The average premium for the new transactions announced (or first discussed) in April was ~56%, and a year-to-date average of 45%.

David Blennerhassett

Asia-Pac M&A Weekly Wrap: The Global, Insignia Financial, National Storage REIT, MCJ, Takara Bio

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)